Open access
Prognostic stratification of patients with biliary tract cancer treated with chemoimmunotherapy: A retrospective multicenter real‐world study
M. Persano
A. Casadei-Gardini
L. Fornaro
T. Satake
O. Abidoye
Federica Lo Prinzi
L. Antonuzzo
J. W. Kim
F. Bergamo
M. Bathon
A. Saborowski
T. Pressiani
C. Vivaldi
I. Rapposelli
F. Peeters
C. Braconi
D. Pinato
E. Tamburini
M. Niger
Stefano Tamberi
F. Castet
M. Verrico
A. Parisi
N. Couto
H. Chon
A. Lamarca
G. Giordano
F. Finkelmeier
E. Oneda
A. Avallone
L. Perkhofer
Il-Hwan Kim
I. Garajová
S. Corallo
E. Fenocchio
Emanuela Dell'Aquila
C. Pirrone
Lorenzo Lucidi
G. Tesini
E. Valenzi
A. Diana
Changhoon Yoo
M. Schirripa
V. Formica
M. Rodriquenz
M. Scartozzi
J. Adeva
M. Ghidini
Gerald W. Prager
G. Aprile
G. Spinelli
Yung-Yeh Su
S. Chan
M. Ikeda
T. Bekaii-Saab
J. Lucchetti
D. Lavacchi
M. Kang
R. Balsano
F. Salani
S. Camera
G. Masi
S. Lonardi
A. Vogel
L. Rimassa
M. Rimini
Medicine
Abstract
The objective of this study is to explore and validate a novel prognostic index for patients with locally advanced or metastatic biliary tract cancer (BTC) treated with first‐line therapy with cisplatin, gemcitabine, and durvalumab.